Incadronic acid

Incadronic acid inhibits growth of Dictyostelium discoideum with an IC50 of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the Ki of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC50 of 48 to 228.6 µM[1].

Product Specifications

CAS Number

[124351-85-5]

UNSPSC

12352211

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/incadronic-acid.html

Purity

98.03

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=P(O)(C(P(O)(O)=O)NC1CCCCCC1)O

Molecular Formula

C8H19NO6P2

Molecular Weight

287.19

References & Citations

[1]Petruczynik P, et al., Three-Component Reaction of Diamines with Triethyl Orthoformate and Diethyl Phosphite and Anti-Proliferative and Antiosteoporotic Activities of the Products. Molecules. 2020 Mar 20;25 (6) :1424.|[2]Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases. WO2006039721.